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Summary
 
Induction of cytotoxic T lymphocyte (CTL) responses against minor histocompatibility antigens
is dependent upon the presence of T cell help and requires the interaction of CD40 on dendritic
cells (DCs) with CD40 ligand on activated T helper cells (Th). This study demonstrates that
CD40 is neither involved in Th-dependent nor Th-independent antiviral CTL responses.
Moreover, the data show that DC maturation occurs in vivo after viral infection in the absence
of CD40 and Th. This maturation did not require viral infection of DCs but was mediated by
 
peptide-specific CD8
 
1
 
 T cells. Surprisingly, naive CD8
 
1
 
 T cells were able to trigger DC matu-
 
ration within 24 h after activation in vivo
 
 and 
 
in vitro. Moreover, peptide-activated CD8
 
1
 
 T
cells were able to induce maturation in trans, as DCs that failed to present the relevant antigen in
vivo also underwent maturation. Upon isolation, the in vivo–stimulated DCs were able to con-
vert a classically Th-dependent CTL response (anti-HY) into a Th-independent response in vitro.
Thus, antiviral CD8
 
1
 
 T cells are sufficient for the maturation of DCs in the absence of CD40.
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I
 
nduction of CTL responses after immunization with mi-
nor histocompatibility antigens, such as the HY antigen,
requires the presence of Th (1, 2). CTL responses induced
by cross-priming, i.e., by priming with exogenous antigens
that reached the class I pathway, have also been shown to
require the presence of Th (3). These observations have
important consequences for tumor therapy, where Th may
be critical for the induction of protective CTL responses by
tumor cells (4). An important effector molecule on acti-
 
vated Th is the CD40 ligand (L)
 
1
 
 interacting with CD40 on
B cells, macrophages, and dendritic cells (DCs) (5). Trigger-
ing of CD40 on B cells is essential for isotype switching and
the generation of B cell memory (5). More recently, it was
shown that stimulation of CD40 on macrophages and DCs
leads to their activation and maturation (6, 7). Specifically,
DCs upregulate costimulatory molecules and produce cyto-
kines, such as IL-12, upon activation. Interestingly, this
CD40L-mediated maturation of DCs seems to be responsi-
ble for the helper effect on CTL responses. In fact, it has
recently been shown that CD40 triggering by Th renders
DCs able to initiate a CTL response (8–10). This is consis-
tent with the earlier observation that Th have to recognize
their ligands on the same APC as the CTLs, indicating that
a cognate interaction is required (3). Thus, CD40L-medi-
ated stimulation by Th leads to the activation of DCs,
which subsequently are able to prime CTL responses.
In contrast to these Th-dependent CTL responses, viruses
are often able to induce protective CTL responses in the
absence of Th (for review, see reference 11). Specifically,
lymphocytic choriomeningitis virus (LCMV) (12–16), ve-
sicular stomatitis virus (VSV; reference 17), influenza virus
(18), vaccinia virus (19), and ectromelia virus (20) were
able to prime CTL responses in mice depleted of CD4
 
1
 
 T
cells or deficient for the expression of class II or CD40.
The mechanism for this Th-independent CTL priming by
viruses is not presently understood. Moreover, most viruses
do not completely stimulate Th-independent CTL responses,
but virus-specific CTL activity is reduced in Th-deficient
mice. Thus, Th may enhance antiviral CTL responses, but
the mechanism of this help is not yet fully understood. DCs
have recently been shown to present influenza-derived an-
tigens by cross-priming (21). It is therefore possible that,
similar to the mechanism shown for minor histocompati-
bility antigens and tumor antigens (8–10), Th may assist in-
duction of CTLs via CD40 triggering on DCs.
This study analyzes the mechanism of Th-independent
versus Th-dependent CTL priming triggered by viruses.
We found that CD40 is not measurably involved in the in-
duction of CTLs specific for LCMV or VSV. Thus, al-
though VSV-specific CTL responses are partly dependent
upon the presence of CD4
 
1
 
 T cells (17), this helper effect
was not mediated by CD40L. However, the virus-specific
 
1
 
Abbreviations used in this paper:
 
 DCs, dendritic cells; L, ligand; LCMV,
lymphocytic choriomeningitis virus; MFI, median fluorescence intensity;
VSV, vesicular stomatitis virus. 
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Mechanism of CD40-independent CTL Induction
 
CTLs were observed to solicit their own help in vivo by
themselves triggering a maturation process in DCs. This
maturation of DCs occurred in complete absence of viral
infection upon injection of specific peptide in a TCR-
transgenic mouse model. The degree of Th independence
of the CTL responses induced by the two different viruses
was paralleled by a correspondingly efficient maturation of
DCs. Interestingly, CD8
 
1
 
 T cells not only mediated activa-
tion of the DCs they were interacting with but also trig-
gered DC maturation in trans, leading to widespread acti-
vation of DCs in lymphoid organs. Thus, in contrast to
minor histocompatibility antigens that only induce abortive
CTL responses in the absence of Th, viruses nucleate a suf-
ficiently strong CTL response that leads to generalized acti-
vation of DCs, rendering the response independent of Th.
 
Materials and Methods
 
Mice and Viruses.
 
Mice deficient for the expression of CD40
(22), MHC class II (23), 
 
b
 
2-microglobulin (24), and RAG-2 (25)
have been described previously. Mice exhibiting a mutation in
their H-2D
 
b
 
 molecule (B6.C–H-2
 
bm13
 
) were provided by Dr. P.
Ohashi, Ontario Cancer Institute, Toronto, Canada. Transgenic
mice expressing a TCR specific for peptide p33 derived from
LCMV presented in association with H-2D
 
b
 
 and transgenic mice
expressing a TCR receptor specific for the HY antigen have been
described previously (26, 27). Mice were bred under specific
pathogen-free conditions according to Swiss federal law. Class
II
 
2
 
/
 
2
 
 mice were back-crossed on a C57BL/6 background, and
C57BL/6 mice were used as controls. CD40
 
1
 
/
 
2
 
 mice were used as
controls for CD40
 
2
 
/
 
2
 
 mice.
The LCMV isolate WE was provided by Dr. P. Ohashi, Tor-
onto, Canada and grown on L cells at a low multiplicity of infec-
tion. VSV serotype Indiana was originally provided by R.M.
Zinkernagel (Institute of Experimental Immunology, Zürich,
Switzerland) and grown on BHK cells at a low multiplicity of
infection.
 
Detection of LCMV- and VSV-specific CTL In Vitro.
 
Mice were
immunized intravenously with LCMV (200 PFU) or VSV (2 
 
3
 
10
 
6
 
 PFU), and 8 or 6 d later, respectively, spleen cell suspensions
were prepared and tested directly in a 
 
51
 
Cr-release assay, using
LCMV-derived peptide p33 (KAVYNFATM)- or VSV-derived
peptide (SDLRGYVYQGLKSG)-pulsed EL-4 cells as target cells
(28). Lytic units were calculated for a 50% level of cell lysis. As
different control mice were used for CD40
 
2
 
/
 
2
 
 versus class II
 
2
 
/
 
2
 
mice, results are expressed as percent lytic units of controls.
 
In Vivo Expansion and Effector Cell Induction.
 
Spleen cells from
TCR-transgenic control mice (10
 
6
 
 cells) were adoptively trans-
ferred into normal C57BL/6 recipient mice. 2 h later, mice were
challenged with LCMV. After 8 d, spleen cells were harvested
and stained for CD8 (PE; PharMingen) and transgenic V
 
a
 
2 ex-
pression (FITC; PharMingen), and the presence of TCR-trans-
genic cells was assessed by 
 
flow cytometric
 
 analysis.
To assess cytolytic effector function, spleen cells were tested in
 
51
 
Cr-release assays using peptide p33 (KAVYNFATM)-pulsed
EL-4 target cells. To distinguish endogenous CTL activity of the
C57BL/6 recipient mice from CTL activity of the transferred
TCR-transgenic T cells, EL-4 cells pulsed with peptide MB6
(KAVVNIATM) were also used as target cells. MB6 is recog-
nized by the TCR-transgenic T cells but not by the polyclonal
C57BL/6 T cells (29).
 
Isolation and Characterization of DC.
 
Mice were immunized in-
travenously with LCMV (200 PFU) or VSV (2 
 
3
 
 10
 
6
 
 PFU). 6 or
5 d later, respectively, spleens of uninfected and virus-infected
mice were dissected, cut into pieces, and digested twice with
collagenase D (Boehringer Mannheim) for 30 min at 37
 
8
 
C in a
shaking water bath. Cells were recovered by centrifugation and
resuspended in an Optiprep™ (Nycomed Pharma) gradient as
previously described (30). Low density cells were then incubated
for 30 min on ice with FITC-labeled anti-CD11c (1:400;
PharMingen) and with PE-labeled anti–B7-1, anti–B7-2, anti-
CD40, and isotype control, in the presence of 5% normal mouse
serum. Cells were washed and analyzed by a FACSCalibur™
flow cytometer (Becton Dickinson), excluding propidium iodide–
positive cells. Percent upregulation of median fluorescence inten-
sity (MFI) was calculated as follows: % upregulation
 
 5 
 
([MFI
induced 
 
2
 
 MFI control]/MFI control 
 
2
 
 1) 
 
3
 
 100.
 
In Vivo–induced DC Maturation by Peptide.
 
Transgenic mice ex-
pressing a TCR specific for LCMV were intravenously injected
with 10 
 
m
 
g LCMV-derived peptide p33 (KAVYNFATM), A4Y
(KAVANFATM), V4Y (KAVVNFATM), or S4Y (KAVSN-
FATM). After 24 h, DCs were isolated from spleens of treated
and, as control, untreated mice and monitored for expression of
B7-1, B7-2, and CD40 as described above. Activation of T cells
was assessed by measuring CD69 (PE) expression on CD8
 
1
 
 T
cells (FITC).
For the T cell stimulation assay, DCs were sorted using a FAC-
Star
 
PLUS™
 
, obtaining a purity 
 
.
 
97%. Different numbers of sorted
DCs (H-2
 
b
 
) were added to 2 
 
3
 
 10
 
4
 
 purified T cells obtained from
spleens of H-2
 
d
 
 BALB/c (MLR) or female HY-transgenic mice
(H-2
 
b 
 
on a RAG-2 background) and cultured in 96-well plates (Fal-
con; Becton Dickinson) for 3 d. T cell proliferation was assessed by
[
 
3
 
H]thymidine (1 
 
m
 
Ci/well) uptake in a 16-h pulse after 72 h.
 
In Vitro Maturation of DC.
 
CD8
 
1
 
 T cells were positively se-
lected from mesenteric LNs of a RAG-2
 
2
 
/
 
2
 
 LCMV-specific,
TCR-transgenic mouse by anti-CD8–coated magnetic beads
(GmbH; Miltenyi Biotec). DCs (10
 
5
 
 cells/well) obtained from
control B6, CD40
 
2
 
/
 
2
 
, and MHC class II
 
2
 
/
 
2
 
 mice were pulsed for
1 h with 10 
 
m
 
g/ml peptide p33, A4Y, V4Y, or S4Y, washed,
and cocultured with 3 
 
3
 
 10
 
5
 
 naive CD8
 
1
 
 
 
T cells at 37
 
8
 
C. After
20 h, DCs were double-stained with FITC-labeled anti-CD11c
and PE-labeled anti–B7-1, anti–B7-2, and anti-CD40 and ana-
lyzed by a FACSCalibur™ flow cytometer, excluding propidium
iodide–positive cells.
 
Generation of Chimeric Mice.
 
RAG-2
 
2
 
/
 
2
 
 mice were irradiated
(3 Gy) and reconstituted with 5 
 
3
 
 10
 
6
 
 bone marrow cells from
CD45.1 congenic C57BL/6 mice and 5 
 
3
 
 10
 
6
 
 bone marrow cells
derived from CD45.2 TCR-transgenic B6.C–H-2
 
bm13 
 
mice. 10 wk
later, recipient mice exhibited large numbers of TCR-transgenic T
cells and a mixed DC population of both CD45.1 and CD45.2 allo-
types. DCs were isolated 24 h after injection of peptide or saline as
described above, triple-stained with APC-labeled anti-CD11c,
FITC-labeled anti-CD45.2, and PE-labeled B7-2, anti-CD40, or
negative control, and analyzed by using a FACSCalibur™ flow cy-
tometer.
 
Results
 
CD40 Is Not Involved in Virus-specific Th-dependent and
-independent CTL Responses.
 
To compare the role of CD4
 
1
 
T cells versus the presence of CD40 for the induction of
LCMV-specific CTL responses, control, CD40
 
2
 
/
 
2
 
, and
MHC class II
 
2
 
/
 
2
 
 
 
mice that lacked Th were immunized 
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with LCMV. At the peak of the response, i.e., 8 d after in-
fection, spleen cells were harvested and tested in a 
 
51
 
Cr-
release assay. To be able to quantify the relative numbers of
CTL effector cells in the different mice, lytic units were
calculated (Fig. 1). Absence of MHC class II or CD40 did
not affect the frequency of CTL precursor after infection
with LCMV.
The Th dependence of the VSV-specific CTL response
was analyzed next. Control, CD40
 
2
 
/
 
2
 
, or MHC class II
 
2
 
/
 
2
 
mice were injected intravenously with VSV, and the pres-
ence of CTLs was assessed 6 d later in a 
 
51
 
Cr-release assay.
In contrast to LCMV-specific CTL responses, VSV-specific
CTL responses were reduced in the absence of Th in
MHC class II
 
2
 
/
 
2
 
 mice by 75–80%. Similar results were ob-
tained in mice depleted of CD4
 
1
 
 Th (data not shown).
However, CTL responses were completely normal in
CD40
 
2
 
/
 
2
 
 mice. Thus, surprisingly, CD40 did not mediate
the Th-dependent component of the VSV-specific CTL
response (Fig. 1).
CD40 and MHC class II have been implicated in thymic
selection (23, 31). We therefore wanted to exclude the
possibility that alterations in the CTL populations in
CD40
 
2
 
/
 
2
 
 or MHC class II
 
2
 
/
 
2
 
 mice were responsible for
the Th independence of the CTL response. Thus, T cells
from transgenic mice expressing a TCR specific for LCMV
(26) were adoptively transferred into the different mice be-
fore viral infection. It has been shown previously that this
leads to a dramatic expansion of transgenic T cells (32). 8 d
after infection, at the peak of the antiviral response, pres-
ence of T cells expressing the transgene-encoded TCR
(V
 
a
 
2) was assessed in the spleens of the mice. The absolute
number and the frequency of transgenic T cells was com-
parable in control, CD40
 
2
 
/
 
2
 
, and MHC class II
 
2
 
/
 
2
 
 mice
(Fig. 2, A and B). Moreover, a comparable lytic activity of
the transgenic cells was observed in a 
 
51
 
Cr-release assay on
peptide p33–pulsed target cells (Fig. 2 C). Similar results
were obtained with peptide MB6, which is selectively
recognized by the transgene-encoded TCR (data not
shown). These results demonstrate that a defined popula-
tion of CTLs expressing a single TCR can be stimulated
by LCMV in the absence of both CD40 molecules and
CD4
 
1
 
 
 
Th.
 
LCMV and VSV Induce Maturation of DCs In Vivo in the
Absence of Th and CD40.
 
DCs have been shown to be
activated in vitro upon stimulation with various inflamma-
tory cytokines and, in particular, after stimulation with
CD40L (33, 34). This activation step leads to a maturation
of DCs that is thought to be essential for the generation of
immune responses (35). The upregulation of costimulatory
molecules on DCs is a hallmark of this maturation step. To
analyze whether viral infection may induce maturation of
DCs in vivo, mice were infected with LCMV, and DCs
were isolated 6 d later from the spleen and directly analyzed
by flow cytometry (Fig. 3). LCMV infection induced the
upregulation of B7-1, B7-2, and CD40 on splenic DCs.
Surprisingly, LCMV infection induced generalized activa-
tion of DCs, as the great majority displayed upregulated
costimulatory molecules. To analyze the role of Th and
CD40 in the activation of DCs, mice deficient for the ex-
pression of MHC class II (and therefore lacking Th) and
CD40
 
2
 
/
 
2
 
 mice were infected with LCMV, and DCs were
Figure 1. CD40 does not mediate Th-dependent antiviral CTL re-
sponses. CD402/2, MHC class II2/2, and respective control mice were
injected intravenously with LCMV (200 PFU) or VSV (2 3 106 PFU),
and spleen cells were isolated 8 or 6 d later, respectively. Spleen cell sus-
pensions were prepared and tested directly in a 51Cr-release assay on pep-
tide-pulsed target cells. As a quantitative measure, lytic units were calcu-
lated per spleen. Lytic units in control mice were: LCMV, 1,020 in
C57BL/6 and 910 in CD401/2; VSV, 930 in C57BL/6 and 210 in
CD401/2. Three mice were used per group. One representative experi-
ment of three is shown.
Figure 2. Normal activation and expansion of LCMV-specific TCR-transgenic T cells in the absence of CD40 or MHC class II. 106 transgenic T cells
expressing a TCR specific for LCMV-derived peptide p33 were transferred into normal, nonirradiated C57BL/6 mice, which were infected intrave-
nously with 200 PFU LCMV 2 h later. Presence of TCR-transgenic mice was assessed 8 d later by flow cytometry (A). Numbers of TCR-transgenic T
cells in the spleen were calculated for the different mice (B). CTL activity was assessed in a 51Cr-release assay on p33-pulsed EL-4 target cells (C). Fre-
quencies of CD81Va21 T cells were ,2% in the absence of infection. Three mice were used per group. One representative experiment of three is
shown. j, control; d, CD402/2; m, class II2/2.1878 Mechanism of CD40-independent CTL Induction
isolated 6 d later (Fig. 3). Maturation of DCs was induced
irrespective of the presence of CD40 or Th, indicating that
DC maturation was triggered by CD81 T cells. However,
DCs also matured in class I2/2 mice (Fig. 3), indicating that
Th are sufficient but not necessary for activation of DCs.
Thus, virus-specific CD41 and CD81 T cells are able to
trigger an activation program in DCs. Taken together,
these data demonstrate that (a) both virus-specific CD81
and CD41 T cells are able to trigger maturation of DCs in
vivo and (b) CD40 is not involved in this process.
LCMV exhibits a high virulence in vivo and is able to
activate T cell responses in the absence of a variety of ac-
cessory molecules. In contrast, VSV exhibits a low viru-
lence in vivo, and T cell responses depend to a higher de-
gree on costimulation (Fig. 1) (11). To analyze whether the
low virulence of VSV may be reflected in inefficient activa-
tion of DCs in vivo after infection, mice were inoculated
with VSV, and splenic DCs were isolated 5 d later (Table
I). Indeed, upregulation of costimulatory molecules on
DCs occurred less efficiently after infection with VSV
compared with LCMV. Thus, the low virulence of VSV
was reflected in inefficient activation of DCs.
Viral Infection Is Not Required for Maturation of DCs.
The majority of splenic DCs exhibited an activated pheno-
type after infection with LCMV. As, by the time of the
analysis, little LCMV was left in the spleen (data not
shown), it was unlikely that only virally infected DCs un-
derwent maturation. However, it remained possible that
few virus-infected DCs nucleated the CTL response that
subsequently activated splenic DCs. To analyze whether
viral infection was required for activation of DCs, trans-
genic mice expressing an MHC class I–restricted TCR spe-
cific for LCMV (26) were injected with the LCMV-
derived peptide p33, and DCs were isolated 1 d later. The
naive CD81 TCR-transgenic T cells were able to induce
maturation of DCs within 24 h after activation in the com-
plete absence of viral infection (Fig. 4). We have recently
developed a panel of altered peptide ligands that trigger
transgenic T cells with various efficiencies (36). Peptide
A4Y behaves as a weak agonist, peptide V4Y behaves as a
partial agonist, and peptide S4Y is a strict antagonist. If
these altered peptide ligands were injected, the efficiency
of the peptides in activating T cells, as assessed by upregula-
tion of CD69 expression (Fig. 4 B), was directly reflected
in their ability to trigger maturation of DCs (Fig. 4 A). In-
terestingly, although peptide A4Y is able to induce prolif-
eration of specific T cells in vitro (36), it fails to efficiently
trigger maturation of DCs in vivo and induced only low
level expression of CD69. This finding is compatible with
the observation that weak antigens generally require the
presence of Th to induce CTL responses in vivo, because
only CD81 T cells interacting with strong agonist peptides
are apparently able to stimulate maturation of DCs, thereby
replacing T help.
CD81 T Cells Can Activate DCs in Trans. Whether a
direct interaction of CD81 T cells with DCs was required
for maturation was analyzed next. To this end, chimeric
mice were generated, using bone marrow from H-2bm13
mice. The TCR of the transgenic mouse line used in our
experiments recognizes peptide p33 presented by H-2Db.
H-2bm13 mice exhibit a mutation in the Db molecule that
does not allow presentation of peptide p33 (37, 38). Thus,
DCs from H-2bm13 mice fail to specifically stimulate TCR-
transgenic T cells, although the TCR-transgenic cells are
efficiently positively selected by H-2bm13 and are reactive to
peptide p33 (37). RAG-22/2 mice were reconstituted with
a mixture of bone marrow derived from CD45.21 H-2bm13
TCR-transgenic mice and bone marrow from CD45.11
C57BL/6 mice. These chimeric mice therefore exhibit a
population of CD45.21 H-2bm13 DCs and a population of
CD45.11 H-2b DCs and express a transgenic TCR specific
for peptide p33 in association with H-2Db. 10 wk after re-
constitution, chimeric mice were injected with peptide p33
or saline, and activation of CD45.11 and CD45.21 DCs
was analyzed. Both CD45.11 DCs (H-2b) that present pep-
tide p33 and CD45.21 DCs (H-2bm13) that fail to present
Figure 3. LCMV-specific CD81 and CD41 T cells can induce matura-
tion of DCs in vivo. C57BL/6 control mice (WT) or CD402/2, MHC
class II2/2, and b2M2/2were infected with LCMV (200 PFU, i.v.). DCs
were isolated from spleens 6 d later, and the expression of B7-1, B7-2,
and CD40 was analyzed by flow cytometry. Results are shown for
CD11c1 DCs. Mean expression values are indicated in the histograms.
One representative experiment of three is shown.
Table I. LCMV Triggers Stronger Upregulation of Costimulatory 
Molecules on DCs than VSV
Percent upregulation* LCMV‡ VSV§
B7-1 310 28
B7-2 395 47
CD40 121 58
*Percent upregulation of MFI was calculated as follows: % upregula-
tion 5 ([MFI induced 2 MFI control]/MFI control 2 1) 3 100.
‡Mice were infected with LCMV (200 PFU), and CD11c1 DCs were
analyzed 6 d later by flow cytometry. As controls, saline-injected trans-
genic mice were used.
§Mice were infected with VSV (2 3 106 PFU/ml), and CD11c1 DCs
were analyzed 5 d later by flow cytometry.1879 Ruedl et al.
peptide p33 exhibited an activated and matured phenotype
after injection of specific peptide (Table II). In contrast,
DCs derived from TCR-transgenic H-2bm13 mice injected
with peptide p33 did not exhibit activated DCs, confirm-
ing that peptide p33 was not presented by H-2bm13 (data
not shown).
CD81 T Cells Can Trigger Maturation of DCs In Vitro.
To analyze CD81 T cell–induced maturation of DCs in a
two-cell coculture system, purified CD81 T cells derived
from TCR-transgenic mice on a RAG-22/2 background
were mixed with freshly isolated, peptide-pulsed splenic
DCs and incubated at 378C for 20 h. Analysis of the ex-
pression of B7-1, B7-2, and CD40 demonstrated efficient
maturation of DCs triggered by peptide-specific CD81 T
cells (Fig. 5). Moreover, as seen in vivo, weak, altered pep-
tide ligands were inefficient at inducing the maturation
program in DCs. As expected, MHC class II2/2 and
CD402/2 DCs matured comparably to control DCs, indi-
cating that the CD81 T cell–mediated maturation of DCs
occurred in the absence of CD40 and Th.
Activated DCs Exhibit an Enhanced Immunogenicity and
Stimulate HY-specific CTLs in the Absence of Th. We next
analyzed the immunogenicity of DCs after activation by
CTLs. Male transgenic mice (H-2b) expressing a TCR spe-
cific for peptide p33 derived from LCMV were injected
with peptide p33 or saline, and splenic DCs were isolated
24 h later and purified by cell sorting (purity .97%). Ti-
Figure 4. Peptide-specific CD81 T cells can induce maturation of
DCs in the absence of viral infection. Transgenic mice expressing a
TCR specific for LCMV-derived peptide p33 were injected with 10
mg of peptide p33, the altered peptide ligands A4Y, V4Y, or S4Y, or
saline. (A) Expression of B7-1, B7-2, and CD40 was analyzed 24 h later by flow cytometry on CD11c1 splenic DCs. (B) Expression of CD69 was
assessed on CD81 T cells. One representative experiment of two is shown.
Table II. CD81 T Cells Can Activate DCs in Trans
Expression
CD11c1 CD45.1 
(H-2b)
CD11c1 CD45.2 
(H-2bm13)
1p33 2p33 1p33 2p33
MFI
B7-2 95 40 114 30
CD40 31 17 36 19
Negative control 5 4 3 4
Chimeric mice were injected with peptide p33, and expression of B7-2 and
CD40 was analyzed for CD45.11 (H-2b) and CD45.21 (H-2bm13) DCs.
Figure 5. CD81 T cells mediated maturation of DCs in vitro. Freshly
isolated splenic DCs derived from control (open bars), CD402/2 (hatched
bars), or MHC class II2/2 (closed bars) were pulsed with peptide p33,
A4Y, V4Y, or S4Y (all at 10 mg/ml) for 1 h at 378C. DCs were washed
and incubated with purified CD81 T cells derived from RAG-22/2,
TCR-transgenic mice. Expression of B7-1 (a), B7-2 (b), and CD40 (c)
was analyzed 20 h later. One representative experiment of four is shown.1880 Mechanism of CD40-independent CTL Induction
trated numbers of DCs were used to stimulate purified al-
lospecific T cells (H-2d) derived from BALB/c mice, and
proliferation was assessed 3 d later by means of [3H]thymi-
dine incorporation. DCs derived from p33-immunized
mice were able to induce efficient proliferation of allospe-
cific T cells, whereas DCs derived from control animals
were barely able to stimulate T cells (Fig. 6 A). Alterna-
tively, DCs were used to stimulate T cells derived from
transgenic mice expressing a TCR specific for HY in asso-
ciation with class I (27). To avoid the contribution of T
cells with endogenous TCR a chains, T cells derived from
HY–TCR-transgenic mice on a RAG-22/2 background
were used. As expected for a Th-dependent CTL response,
control DCs stimulated only low-level proliferation of spe-
cific T cells. In contrast, CTL-activated DCs derived from
p33-primed animals triggered much stronger proliferation
of specific T cells (Fig. 6 B). Thus, CTL-mediated activa-
tion of DCs rendered Th-dependent CD81 T cell re-
sponses largely Th independent.
Discussion
This study demonstrates that maturation of DCs occurs
in vivo after viral infection in the absence of Th and CD40.
Surprisingly, this Th-independent maturation was triggered
by virus-specific CD81 T cells and not by the viral infec-
tion per se. Moreover, the matured DCs were able to in-
duce a classically Th-dependent CTL response in the ab-
sence of Th, indicating that antiviral CD81 T cells can
replace Th in vivo. These results help explain why viruses
are able to trigger Th-independent CTL responses, and
highlight important differences between virus- and tumor-
specific CTL responses.
Viruses Trigger Th-independent CTL Responses. It has been
known for some time that viruses are able to stimulate pro-
tective CTL responses in the absence of CD41 T cells (12–
20). However, CTL responses are impaired in the absence
of Th after infection with poorly replicating viruses such
as VSV (17). To date, it has not been analyzed whether
CD41 T cells assist CTLs via a CD40L-dependent mecha-
nism under these circumstances. This study demonstrates
that this is not the case. Thus, even the Th-dependent part
of a virus-specific CTL response is not dependent upon the
CD40–CD40L interaction. Compared with tumor-specific
CTL responses, where Th assist CTL induction by activat-
ing DCs via CD40 triggering, the Th-dependent produc-
tion of cytokines, such as IL-2, seems to be more important
during viral infections. This interpretation is consistent
with the previous observation that cytokine secretion by
Th after viral infection is not impaired in the absence of
CD40 (39).
DC Maturation Triggered by CD81 T Cells. A large pro-
portion of DCs isolated from virally infected mice exhib-
ited a mature phenotype. This maturation of DCs occurred
in the absence of Th and CD40. Various stimuli are known
to activate DCs. Specifically, microbial components, such
as LPS, bacterial DNA, or cell walls; inflammatory cyto-
kines; and CD40 triggering are able to stimulate expression
of costimulatory molecules on DCs and induce their mi-
gration to central lymphoid organs (6, 7). Moreover, it has
been shown that LPS is able to activate splenic DCs in vivo
and trigger the migration of DCs from the red pulp to T
cell areas (40). Interestingly, infection of splenic APCs by
influenza virus directly induces the expression of costimula-
tory molecules and enhances the immunogenicity of DCs
(8, 41). Thus, it was possible that the observed Th-inde-
pendent maturation of DCs was (a) directly mediated by
viral components, (b) mediated by non-T cells such as NK
cells, or (c) mediated by CD81 T cells. To address this
question, various gene-deficient mice were infected with
LCMV, and the maturation of DCs was assessed. Matura-
tion of DCs occurred in class II2/2 as well as class I2/2
Figure 6. CD81 T cell–mediated activation of DCs renders Th-depen-
dent CD81 T cell responses Th independent. Male transgenic mice (H-2b)
expressing a TCR specific for LCMV-derived peptide p33 were injected
with 1 mg of peptide p33 (or saline), and DCs were isolated 24 h later by
FACS® sorting. Titrated numbers of DCs isolated from p33-primed ani-
mals (h) or control animals (j) were used to stimulate purified allospe-
cific T cells from BALB/c mice (A) or HY-specific, TCR-transgenic T
cells (B). To avoid contribution of endogenous TCR chains, HY–TCR-
transgenic mice on a RAG-22/2 background were used for the experi-
ments. Proliferation was assessed after 72 h. One representative experi-
ment of two is shown.1881 Ruedl et al.
mice. These results demonstrated that DC maturation
could be mediated by either CD41 or CD81 T cells. DCs
isolated from transgenic mice expressing a class I–restricted
TCR 24 h after injection of specific peptide also exhibited
an activated phenotype. This demonstrated that DC matu-
ration triggered by CD81 T cells could occur in complete
absence of viral infection. Interestingly, the maturation
stimulus delivered by CD81 T cells was not dependent
upon a direct interaction of CD81 T cells with DCs. In
contrast, CD81 T cells could activate DCs in trans, and
DCs that failed to present the relevant peptide due to a
mutation in the class I molecule also underwent maturation
in TCR-transgenic mice injected with peptide. Thus,
freshly activated CD81 T cells are able to induce general-
ized activation of DCs, even in the absence of direct T
cell–DC contact.
There are parallels between the activation of DCs by
CD81 T cells described here and the IFN system. Type I
IFNs induce an antiviral state in many different cell types.
This antiviral state is induced in trans, i.e., virally infected
cells are able to stimulate neighboring cells via secretion of
type I IFNs. Similarly, CD81 T cells induce an immuno-
stimulatory state, not only in virally infected DCs that
present the relevant peptides but also in neighboring APCs.
However, the two systems are apparently not identical, be-
cause (a) type I IFNs induce an antiviral rather than an im-
munostimulatory state in DCs and (b) DC activation by
CD81 T cells occurs in the absence of functional type IFN
receptors (data not shown).
Using the in vitro system of CD81 T cell–mediated DC
activation and T cells or DCs derived from various gene-
deficient mice together with neutralizing antibodies and
other blocking molecules, we tried to define the factor re-
sponsible for the observed maturation of DCs. So far, we
can exclude maturation mediated by CD28, CD40L,
TRANCE, TNF, IL-1, IL-4, IL-6, IL-17, IFN-a/b, and
IFN-g, but have not yet identified the critical molecule.
Future studies will therefore address the cloning of the as
yet elusive factor.
Th-independent CTL Responses: a Threshold Phenomenon?
It has been observed that viruses are able to generate CTL
responses in the absence of Th (12–20). Interestingly, those
viruses that induced strong CTL responses in the presence
of Th also did so in the absence of Th, suggesting that the
Th dependence of the response may simply be determined
by the overall strength of the response. Along a similar line,
recombinant viral proteins injected in association with in-
sect cell debris as an adjuvant were able to induce very
strong CTL responses by cross-priming (42), and this cross-
priming occurred in the absence of Th (42). Thus, the fail-
ure of model antigens to induce CTL responses in the
absence of Th is not absolute but rather seems to be de-
termined by the strength of the response. The results pre-
sented here may provide an explanation for these findings
by suggesting that generation of CTL responses may occur
as a threshold phenomenon due to a positive feedback
mechanism. Accordingly, virus-infected DCs are able to ac-
tivate a few naive CTLs. These activated T cells in turn se-
crete inflammatory cytokines/chemokines that may lead to
the activation of neighboring APCs. The number of CD81
T cells that can be activated in such a way determines the ef-
ficiency of DC activation. Thus, if only few CD81 T cells
are activated initially, the response may be abortive, as too
few DCs undergo maturation. In contrast, if a sufficient
number of CTLs is triggered, widespread activation of DCs
may occur, and an immunostimulatory program is initiated
in lymphoid organs that renders the response independent
of Th. Thus, during tumor-specific responses or upon cross-
priming, few CD81 T cells are activated, and the response
remains abortive in the absence of Th, whereas during anti-
viral immune responses, a sufficient number of CD81 T
cells becomes triggered to render the response Th indepen-
dent. In this model, VSV may represent an intermediate
case. It induces only weak upregulation of costimulatory
molecules in vivo. Correspondingly, CTL responses partly
depend on the presence of Th.
Interestingly, the requirements for activation of DCs
were very stringent. Peptide A4Y, which is a relatively
weak agonist that nevertheless stimulates efficient prolifera-
tion of specific T cells in vitro, almost completely failed to
trigger the activation program in DCs in vivo. Thus, only
T cells interacting with strong agonists are able to stimulate
maturation of DCs, offering an explanation for why many
model antigens that are often weak agonists compared with
viral peptides require Th for induction of CTL responses.
This study demonstrates that CD81 T cells can mediate
activation of DCs in complete absence of viral infection.
However, it should be noted that a cross-talk between the
innate and specific immune systems during viral infection
may also facilitate the induction of Th-independent CTL
responses. Thus, although CD81 T cells can solicit their
own help by themselves inducing maturation of DCs, other
factors are likely to contribute to the efficiency of antiviral
CTL responses (11).
Autoimmunity Triggered by Viruses: Are Activated DCs the
Missing Link? Viral infections are thought to be an im-
portant cause for the induction or exacerbation of auto-
immune diseases (43). It has been argued that cross-reactive
T cells are responsible for disease, and it has been shown
that viral peptides can stimulate autoreactive T cell clones
(44, 45). Moreover, there is good evidence that Herpes
Simplex virus causes autoimmune stromal keratitis by acti-
vating self-specific, cross-reactive T cells (46). However,
cross-reactive T cells are not always the critical factor for
disease. In the case of Coxsackie virus–induced diabetes, it
has been shown that the disease is mediated by T cells rec-
ognizing self-antigens that do not cross-react with viral
proteins. These self-antigens were apparently released from
lysed virus-infected cells and subsequently activated the
self-specific T cells (47). However, presence of these anti-
gens alone may not be sufficient for the induction of self-
specific T cells, because low amounts of most self-antigens
also reach lymphoid organs in the absence of infection due
to physiological cell turnover (48). Thus, the presentation
of self-antigens in lymphoid organs per se does not seem to
be responsible for the induction of autoimmunity, likely1882 Mechanism of CD40-independent CTL Induction
because immature DCs in lymphoid organs that process
those antigens most efficiently are inefficient at stimulating
naive T cells. However, the nonspecific maturation of DCs
and the concomitant upregulation of costimulatory mole-
cules triggered by the antiviral immune response may be
responsible for the activation of self-specific T cells that
usually ignore their antigens in vivo. The generalized acti-
vation of DCs upon viral infection may therefore not only
boost virus-specific T cell responses and render them inde-
pendent of Th but may also shift the balance from igno-
rance to autoimmunity.
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